RxDoctor Payments Data

Lavina Gagnon, PA

Physician Assistant · Hartford, CTNPI 1962557207

Payments from drug & device makers

$1,249in general payments, 2019–2025

Across 41 payments — averaging $30.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$367
  • Abbott$190
  • AbbVie$141
  • GSK$124
  • Zealand Pharma US, Inc.$116
  • Novo Nordisk$92
  • plus $219 from 5 others

What the payments were for

  • Food & beverage$1,249100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,249 in reported general payments places this provider in the 80th percentile of 1,795 physician assistant providers in Connecticut.

See all physician assistant providers in Connecticut

Medicare billing

Part B allowed, 2024
$38,736
Medicare patients
231
Services billed
414

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide28$43,100
MounjaroTirzepatide19$20,267
TrulicityDulaglutide12$11,797
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$9,842
Breo ElliptaFluticasone/Vilanterol11$5,225
SynthroidLevothyroxine Sodium23$1,935
Lantus SolostarInsulin Glargine,hum.Rec.Anlog21$1,889
Albuterol Sulfate HfaAlbuterol Sulfate62$941
Atorvastatin Calcium81$891
Rosuvastatin Calcium48$687
Econazole Nitrate13$512
Omeprazole30$506
Doxycycline Monohydrate47$437
Famotidine35$396
Pantoprazole Sodium34$386

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$92$43,10028 claims
Lilly USA, LLCMounjaro, Trulicity$92$32,06331 claims
GSKTrelegy Ellipta, Breo Ellipta$124$15,06626 claims
AbbVieSynthroid$141$1,93523 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,795 physician assistant providers in Connecticut.

Other physician assistant in Hartford

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →